Progression of Barrett oesophagus: Role of endoscopic and histological predictors

Nature Reviews Gastroenterology and Hepatology

Volumn 11, Issue 9, 2014, Pages 525-534

  Anaparthy, Rajeswari ^a   Sharma, Prateek ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARRETT ESOPHAGUS; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; ENDOSCOPIC THERAPY; ERADICATION THERAPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS DYSPLASIA; GASTROESOPHAGEAL REFLUX; HIATUS HERNIA; HISTOPATHOLOGY; HUMAN; PHOTODYNAMIC THERAPY; PREDICTOR VARIABLE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT;

ADENOCARCINOMA; BARRETT ESOPHAGUS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; FORECASTING; HERNIA, HIATAL; HUMANS; RECURRENCE; RISK FACTORS;

EID: 84906891191     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2014.69     Document Type: Review

References (74)

1. Pohl, H. & Welch, H. G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J. Natl Cancer Inst. 97, 142-146 (2005).
2. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 64, 9-29 (2014).
3. Hur, C. et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer 119, 1149-1158 (2013).
4. Reid, B. J., Blount, P. L. & Rabinovitch, P. S. Biomarkers in Barrett's esophagus. Gastrointest. Endosc. Clin. N. Am. 13, 369-397 (2003).
5. Tischoff, I. & Tannapfel, A. Barrett's esophagus: can biomarkers predict progression to malignancy? Expert Rev. Gastroenterol. Hepatol. 2, 653-663 (2008).
6. Prasad, G. A. et al. Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology 135, 370-379 (2008).
7. Bansal, A. et al. Feasibility of microRNAs as biomarkers for Barrett's esophagus progression: a pilot cross-sectional, phase 2 biomarker study. Am. J. Gastroenterol. 106, 1055-1063 (2011).
8. Varghese, S., Lao-Sirieix, P. & Fitzgerald, R. C. Identification and clinical implementation of biomarkers for Barrett's esophagus. Gastroenterology 142, 435-441 (2012).
9. Paterson, A. L. & Fitzgerald, R. C. Biomarkers in Barrett's oesophagus and oesophageal adenocarcinoma. Expert Opin. Med. Diagn. 1, 363-376 (2007).
10. Prasad, G. A., Bansal, A., Sharma, P. & Wang, K. K. Predictors of progression in Barrett's esophagus: current knowledge and future directions. Am. J. Gastroenterol. 105, 1490-1502 (2010).
11. Theisen, J. et al. Preoperative chemotherapy unmasks underlying Barrett's mucosa in patients with adenocarcinoma of the distal esophagus. Surg. Endosc. 16, 671-673 (2002).
12. Sharma, P. Clinical practice. Barrett's esophagus. N. Engl. J. Med. 361, 2548-2556 (2009).
13. Lagergren, J., Bergstrom, R., Lindgren, A. & Nyren, O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med. 340, 825-831 (1999).
14. Eloubeidi, M. A., Mason, A. C., Desmond, R. A. & El-Serag, H. B. Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? Am. J. Gastroenterol. 98, 1627-1633 (2003).
15. Wang, K. K. & Sampliner, R. E. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am. J. Gastroenterol. 103, 788-797 (2008).
16. Corley, D. A., Levin, T. R., Habel, L. A., Weiss, N. S. & Buffler, P. A. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 122, 633-640 (2002).
17. Ferguson, M. K. & Durkin, A. Long-term survival after esophagectomy for Barrett's adenocarcinoma in endoscopically surveyed and nonsurveyed patients. J. Gastrointest. Surg. 6, 29-35 (2002).
18. Spechler, S. J., Sharma, P., Souza, R. F., Inadomi, J. M. & Shaheen, N. J. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 140, 1084-1091 (2011).
19. Sikkema, M., de Jonge, P. J., Steyerberg, E. W. & Kuipers, E. J. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 8, 235-244 (2010).
20. Jung, K. W. et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study. Am. J. Gastroenterol. 106, 1447-1455 (2011).
21. Anderson, L. A. et al. Mortality in Barrett's oesophagus: results from a population based study. Gut 52, 1081-1084 (2003).
22. Schouten, L. J. et al. Total cancer incidence and overall mortality are not increased among patients with Barrett's esophagus. Clin. Gastroenterol. Hepatol. 9, 754-761 (2011).
23. Bedi, A. O. et al. A survey of expert follow-up practices after successful endoscopic eradication therapy for Barrett's esophagus with high-grade dysplasia and intramucosal adenocarcinoma. Gastrointest. Endosc. 78, 696-701 (2013).
24. Cameron, A. J. Barrett's esophagus: prevalence and size of hiatal hernia. Am. J. Gastroenterol. 94, 2054-2059 (1999).
25. Avidan, B. et al. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am. J. Gastroenterol. 97, 1930-1936 (2002).
26. Weston, A. P. et al. Risk stratification of Barrett's esophagus: updated prospective multivariate analysis. Am. J. Gastroenterol. 99, 1657-1666 (2004).
27. Patti, M. G. et al. Hiatal hernia size affects lower esophageal sphincter function, esophageal acid exposure, and the degree of mucosal injury. Am. J. Surg. 171, 182-186 (1996).
28. Ouatu-Lascar, R., Fitzgerald, R. C. & Triadafilopoulos, G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 117, 327-335 (1999).
29. Fitzgerald, R. C., Omary, M. B. & Triadafilopoulos, G. Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. J. Clin. Investig. 98, 2120-2128 (1996).
30. Pohl, H. et al. Risk factors in the development of esophageal adenocarcinoma. Am. J. Gastroenterol. 108, 200-207 (2013).
31. Sikkema, M. et al. Predictors for neoplastic progression in patients with Barrett's esophagus: a prospective cohort study. Am. J. Gastroenterol. 106, 1231-1238 (2011).
32. Menke-Pluymers, M. B., Hop, W. C., Dees, J., van Blankenstein, M. & Tilanus, H. W. Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett) esophagus. The Rotterdam Esophageal Tumor Study Group. Cancer 72, 1155-1158 (1993).
33. Weston, A. P., Badr, A. S. & Hassanein, R. S. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma. Am. J. Gastroenterol. 94, 3413-3419 (1999).
34. Wong, T., Tian, J. & Nagar, A. B. Barrett's surveillance identifies patients with early esophageal adenocarcinoma. Am. J. Med. 123, 462-467 (2010).
35. Wani, S. et al. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin. Gastroenterol. Hepatol. 9, 220-227 (2011).
36. Thomas, T., Abrams, K. R., De Caestecker, J. S. & Robinson, R. J. Meta analysis: cancer risk in Barrett's oesophagus. Aliment. Pharmacol. Ther. 26, 1465-1477 (2007).
37. Rudolph, R. E. et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann. Int. Med. 132, 612-620 (2000).
38. Yousef, F. et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am. J. Epidemiol. 168, 237-249 (2008).
39. Bhat, S. et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J. Natl Cancer Inst. 103, 1049-1057 (2011).
40. Anaparthy, R. et al. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia. Clin. Gastroenterol. Hepatol. 11, 1430-1436 (2013).
41. Buttar, N. S. et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 120, 1630-1639 (2001).
42. Tharavej, C. et al. Predictive factors of coexisting cancer in Barrett's high-grade dysplasia. Surg. Endosc. 20, 439-443 (2006).
43. Peters, F. P. et al. Histologic evaluation of resection specimens obtained at 293 endoscopic resections in Barrett's esophagus. Gastrointest. Endosc. 67, 604-609 (2008).
44. Montgomery, E. et al. Are ulcers a marker for invasive carcinoma in Barrett's esophagus? Data from a diagnostic variability study with clinical follow-up. Am. J. Gastroenterol. 97, 27-31 (2002).
45. Giacchino, M. A clinical prediction model to risk-stratify patients with Barrett's esophagus (BE): Results from a large, multicenter cohort [abstract 342]. Gastroenterology 144 (Suppl. 1), S71-S72 (2013).
46. Hull, M. J. et al. Endoscopic mucosal resection: an improved diagnostic procedure for early gastroesophageal epithelial neoplasms. Am. J. Surg. Pathol. 30, 114-118 (2006).
47. Chennat, J. et al. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma-an American single-center experience. Am. J. Gastroenterol. 104, 2684-2692 (2009).
48. Lee, M. H., Buterbaugh, K., Richards-Kortum, R. & Anandasabapathy, S. Advanced endoscopic imaging for Barrett's esophagus: current options and future directions. Curr. Gastroenterol. Rep. 14, 216-225 (2012).
49. Spechler, S. J., Sharma, P., Souza, R. F., Inadomi, J. M. & Shaheen, N. J. American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology 140, e18-e52 (2011).
50. Srivastava, A. et al. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus. Am. J. Gastroenterol. 102, 483-493 (2007).
51. Wani, S. et al. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. Gastroenterology 141, 1179-1186 (2011).
52. Dar, M. S., Goldblum, J. R., Rice, T. W. & Falk, G. W. Can extent of high grade dysplasia in Barrett's oesophagus predict the presence of adenocarcinoma at oesophagectomy? Gut 52, 486-489 (2003).
53. Hvid-Jensen, F., Pedersen, L., Drewes, A. M., Sorensen, H. T. & Funch-Jensen, P. Incidence of adenocarcinoma among patients with Barrett's esophagus. N. Engl. J. Med. 365, 1375-1383 (2011).
54. Sharma, P. et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin. Gastroenterol. Hepatol. 4, 566-572 (2006).
55. Wani, S., Choi, W. & Sharma, P. Low-grade dysplasia in Barrett's esophagus-an innocent bystander? Pro. Endoscopy 39, 643-646 (2007).
56. Wani, S., Mathur, S. & Sharma, P. How to manage a Barrett's esophagus patient with low-grade dysplasia. Clin. Gastroenterol. Hepatol. 7, 27-32 (2009).
57. Downs-Kelly, E. et al. Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett's esophagus biopsies. Am. J. Gastroenterol. 103, 2333-2340 (2008).
58. Montgomery, E. et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum. Pathol. 32, 368-378 (2001).
59. Alikhan, M. et al. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest. Endosc. 50, 23-26 (1999).
60. Curvers, W. L. et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am. J. Gastroenterol. 105, 1523-1530 (2010).
61. Schnell, T. G. et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 120, 1607-1619 (2001).
62. Reid, B. J., Levine, D. S., Longton, G., Blount, P. L. & Rabinovitch, P. S. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low-and high-risk patient subsets. Am. J. Gastroenterol. 95, 1669-1676 (2000).
63. Rastogi, A. et al. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest. Endosc. 67, 394-398 (2008).
64. Gaddam, S. et al. Persistence of non-dysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma-results from a large multicenter cohort. Gastroenterology 145, 548-553 (2013).
65. Thrift, A. P., Kendall, B. J., Pandeya, N., Vaughan, T. L. & Whiteman, D. C. A clinical risk prediction model for Barrett esophagus. Cancer Prev. Res. (Phila.) 5, 1115-1123 (2012).
66. Rubenstein, J. H. et al. Prediction of Barrett's esophagus among men. Am. J. Gastroenterol. 108, 353-362 (2013).
67. Bird-Lieberman, E. L. et al. Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus. Gastroenterology 143, 927-935 (2012).
68. Sato, F. et al. Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features. PLoS ONE 3, e1890 (2008).
69. Evans, J. A. et al. The role of endoscopy in Barrett's esophagus and other premalignant conditions of the esophagus. Gastrointest. Endosc. 76, 1087-1094 (2012).
70. Pech, O. et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 57, 1200-1206 (2008).
71. Bulsiewicz, W. J. et al. Predictors of recurrent Barrett's esophagus after successful radiofrequency ablation in a nationwide, multicenter cohort: results from the U.S. RFA Registry [abstract 3]. Gastroenterology 144 (Suppl.1), S1 (2013).
72. Haidry, R. J. et al. Radiofrequency ablation and endoscopic mucosal resection for dysplastic barrett's esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry. Gastroenterology 145, 87-95 (2013).
73. Badreddine, R. J. et al. Prevalence and predictors of recurrent neoplasia after ablation of Barrett's esophagus. Gastrointest. Endosc. 71, 697-703 (2010).
74. Gupta, M. et al. Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett's esophagus: results from a US Multicenter Consortium. Gastroenterology 145, 79-86 (2013).